This is a small, early-stage royalty investment consistent with Ligand's business model. No material near-term financial impact. Monitor AvenCell's clinical milestones for AVC-201 (Phase 1b AML data) and AVC-203 (Phase 1a initiation) to assess potential future royalty value.
Price Chart
Executive Summary
Ligand Pharmaceuticals entered into a financing agreement with AvenCell Therapeutics for up to $47 million, comprising up to $41 million in exchange for a mid single-digit to low double-digit royalty on worldwide net sales of AvenCell's pipeline (including AVC-201 and AVC-203) and up to $6 million in Series C equity. The capital is structured in four tranches tied to clinical milestones. This is a routine royalty-aggregation investment for Ligand, adding a preclinical/early-stage cell therapy asset to its portfolio with no near-term revenue impact.
Key Facts
- Ligand committed up to $41 million for a mid single-digit to low double-digit royalty on worldwide net sales of AvenCell's current and future pipeline assets.
- Ligand also committed up to $6 million in concomitant Series C financing in AvenCell.
- The $41 million royalty capital will be funded in four tranches, with the first payable at closing and the remaining three upon achievement of predetermined clinical milestones.
- AvenCell's lead program AVC-201 is in a Phase 1b expansion trial for relapsed/refractory AML; AVC-203 is a Phase 1a program for B-cell malignancies.
- No financial terms (revenue, EPS, cash position, guidance) were disclosed in this filing.
Financial Impact
Up to $47 million total commitment ($41M royalty + $6M equity) with no near-term revenue contribution; royalty stream is contingent on clinical and commercial success of early-stage assets.
Risk Factors
- AvenCell's pipeline is early-stage (Phase 1b/1a); clinical failure or delays would eliminate royalty value.
- The $41 million is committed in tranches contingent on milestones — if milestones are not met, Ligand may not deploy the full amount.
- Cell therapy manufacturing and scalability risks could delay or prevent commercialization.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000886163-26-000054 |
| Document: lgnd_avencellreleasex20260.htm | 0000886163-26-000054 |
| Document: 0000886163-26-000054-index-headers.html | 0000886163-26-000054 |
| Document: 0000886163-26-000054-index.html | 0000886163-26-000054 |
| Document: 0000886163-26-000054.txt | 0000886163-26-000054 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $307.64 | awaiting T+20 | awaiting T+20 | $311.73 (+1.33%) |
Oct 15, 2026 12d ago | Press Release | $298.50 | awaiting T+20 | awaiting T+20 | $311.73 (+4.43%) |
Sep 24, 2026 4w ago | 8-K | $299.04 $307.82 | ▲ +2.94% | ▲ +3.36% | $311.73 (+4.24%) |
Sep 22, 2026 5w ago | 8-K | $298.50 $306.40 | ▲ +2.65% | ▲ +3.21% | $311.73 (+4.43%) |
Sep 14, 2026 6w ago | Insider Cluster | $276.98 $303.53 | ▲ +9.59% | ▲ +6.86% | $311.73 (+12.55%) |
Aug 14, 2026 10w ago | Insider Cluster | $291.77 $276.98 | ▼ −5.07% | ▼ −3.09% | $311.73 (+6.84%) |
Aug 6, 2026 11w ago | 8-K | $300.14 $289.74 | ▼ −3.46% | ▼ −4.06% | $311.73 (+3.86%) |
Jun 25, 2026 17w ago | 8-K | $303.59 $302.15 | ▼ −0.47% | ▼ −1.74% | $311.73 (+2.68%) |
Jun 18, 2026 18w ago | Insider Cluster | $274.88 $296.45 | ▲ +7.85% | ▲ +7.31% | $311.73 (+13.41%) |
Jun 15, 2026 19w ago | Insider Cluster | $255.25 $300.97 | ▲ +17.91% | ▲ +17.71% | $311.73 (+22.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers